{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:49:37Z","timestamp":1761648577834,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.aohep.2021.100337","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T09:50:34Z","timestamp":1615110634000},"page":"100337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["\u2018Real-life\u2019 experience with direct-acting antiviral agents for HCV after kidney transplant"],"prefix":"10.1016","volume":"25","author":[{"given":"Fabrizio","family":"Fabrizi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Palazzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Anders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Virginia","family":"Reggiardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Cheinquer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Grazia Videla","family":"Zuain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Figueroa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Mendizabal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezequiel","family":"Ridruejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.aohep.2021.100337_bib0005","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrneph.2015.5","article-title":"Hepatitis C and its impact on renal transplantation","volume":"11","author":"Morales","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.aohep.2021.100337_bib0010","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0272-6386(97)90345-0","article-title":"The impact of renal transplantation on survival in hepatitis C positive end-stage renal disease patients","volume":"29","author":"Knoll","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.aohep.2021.100337_bib0015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/hep.510290123","article-title":"Impact of hepatitis B and C virus on kidney transplantation outcome","volume":"29","author":"Mathurin","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2021.100337_bib0020","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/jvh.12148","article-title":"Meta-analysis of observational studies: hepatitis C and survival after renal transplant","volume":"21","author":"Fabrizi","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.aohep.2021.100337_bib0025","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.kisu.2018.06.001","article-title":"KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease","volume":"8","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group","year":"2018","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.aohep.2021.100337_bib0030","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.nefro.2019.01.002","article-title":"Hepatitis C and kidney transplant. The eradication time has arrived","volume":"39","author":"Esforzado","year":"2019","journal-title":"Nefrologia"},{"key":"10.1016\/j.aohep.2021.100337_bib0035","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1007\/s10620-015-3801-y","article-title":"Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systematic review and meta-analysis","volume":"60","author":"Fabrizi","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.aohep.2021.100337_bib0040","unstructured":"AASLD (American Association for the Study of Liver Diseases) and IDSA (Infectious Disease Society of America): HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. http:\/\/hcvguidelines.org Last update August 27, 2020."},{"key":"10.1016\/j.aohep.2021.100337_bib0045","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1503\/cjs.023811","article-title":"Research funded by the industry","volume":"54","author":"Harvey","year":"2011","journal-title":"Can J Surg"},{"key":"10.1016\/j.aohep.2021.100337_bib0050","unstructured":"NEHI (Network for Excellence in Health Innovation). Real world evidence: a new era for healthcare innovation, September 2015. https:\/\/www.nehi.net\/writable\/publication_files\/file\/rwe_issue_brief_final.pdf. Accessed March 7, 2016."},{"key":"10.1016\/j.aohep.2021.100337_bib0055","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.aohep.2021.100337_bib0060","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement. Guidelines for reporting observational studies","volume":"12","author":"Von Elm","year":"2014","journal-title":"Int J Surg"},{"key":"10.1016\/j.aohep.2021.100337_bib0065","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1111\/ajt.13620","article-title":"Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents","volume":"16","author":"Sawinski","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.aohep.2021.100337_bib0070","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.transproceed.2020.01.021","article-title":"Eliminating hepatitis C virus from a prevalent kidney transplant recipient population: a single-center study in Belgium in the direct-acting antivirals era","volume":"52","author":"Devresse","year":"2020","journal-title":"Transplant Proc"},{"key":"10.1016\/j.aohep.2021.100337_bib0075","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jhep.2016.12.020","article-title":"Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C","volume":"66","author":"Fernandez","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2021.100337_bib0080","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/M16-1205","article-title":"Treatment with ledipasvir-sofosbuvir or 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial","volume":"166","author":"Colombo","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.aohep.2021.100337_bib0085","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/ajt.13518","article-title":"Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation","volume":"16","author":"Kamar","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.aohep.2021.100337_bib0090","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1097\/TXD.0000000000000744","article-title":"Eight weeks of ledipasvir\/sofosbuvir in kidney transplant recipients with hepatitis C genotype 1 infection","volume":"3","author":"Husson","year":"2017","journal-title":"Transplant Direct"},{"key":"10.1016\/j.aohep.2021.100337_bib0095","first-page":"e419","article-title":"Treatment with grazoprevir\/elbasvir fo renal transplant recipients with chronic hepatitis C virus infection and impaired allograft function","volume":"4","author":"Eisenberger","year":"2018","journal-title":"Transplant Direct"},{"key":"10.1016\/j.aohep.2021.100337_bib0100","doi-asserted-by":"crossref","first-page":"e12941","DOI":"10.1111\/ctr.12941","article-title":"Ledipasvir\/sofosbuvir is effective and well tolerated in post kidney transplant patients with chronic hepatitis C virus","volume":"31","author":"Morales","year":"2017","journal-title":"Clin Transplant"},{"key":"10.1016\/j.aohep.2021.100337_bib0105","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8953581","article-title":"Eradication of HCV in renal transplant recipients and its effects on quality of life","author":"Sabbatini","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.aohep.2021.100337_bib0110","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1016\/j.transproceed.2020.06.005","article-title":"Chronic hepatitis C virus infection after kidney transplantation with or without direct-acting antivirals in a real-life setting: a French multicenter experience","volume":"52","author":"Chevallier","year":"2020","journal-title":"Transplant Proc"},{"key":"10.1016\/j.aohep.2021.100337_bib0115","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","article-title":"Pharmacokinetic, pharmacodynamics, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir","volume":"54","author":"Kirby","year":"2015","journal-title":"Clin Pharmacokinetic"},{"key":"10.1016\/j.aohep.2021.100337_bib0120","unstructured":"Center for Drug Evaluation and Research. Sofosbuvir Clinical Pharmacology and Biopharmaceutics Review. Available at: https:\/\/www.ccessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204671Orig1s000ClinPharmR. Accessed July 2, 2020."},{"key":"10.1016\/j.aohep.2021.100337_bib0125","first-page":"85","article-title":"Sofosbuvir antiviral therapy in HCV patients with severe renal failure","volume":"40","author":"Rodriguez Gill","year":"2017","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2021.100337_bib0130","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"HCV-TARGET. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"36","author":"Saxena","year":"2016","journal-title":"Liver Int"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268121000363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268121000363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:43:51Z","timestamp":1761648231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268121000363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":26,"alternative-id":["S1665268121000363"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2021.100337","relation":{},"ISSN":["1665-2681"],"issn-type":[{"type":"print","value":"1665-2681"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u2018Real-life\u2019 experience with direct-acting antiviral agents for HCV after kidney transplant","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2021.100337","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"100337"}}